Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.55 USD | -1.50% | -4.90% | +65.20% |
15/05 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
13/05 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.20% | 143.19Cr | |
+9.99% | 12TCr | |
+12.01% | 11TCr | |
-3.07% | 2.47TCr | |
-0.93% | 2.2TCr | |
-5.43% | 1.93TCr | |
-6.90% | 1.76TCr | |
-39.36% | 1.73TCr | |
+5.82% | 1.4TCr | |
+33.05% | 1.21TCr |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-12-2022 10